Quantcast

Latest Experimental cancer treatments Stories

2014-04-16 14:11:59

A University of Texas at Arlington physicist working to create a luminescent nanoparticle to use in security-related radiation detection may have instead happened upon an advance in photodynamic cancer therapy. Wei Chen, professor of physics and co-director of UT Arlington's Center for Security Advances Via Applied Nanotechnology, was testing a copper-cysteamine complex created in his lab when he discovered unexplained decreases in its luminescence, or light emitting power, over a...

2014-04-14 12:33:03

CALGARY, April 14, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that a poster authored by Bolton, et al was presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. The poster, titled "Resistance to oncolytic reovirus is associated with high expression of Yes-Associated Protein (YAP-1) in head and neck cancer," covered preclinical research focused on identifying biomarkers...

2014-04-11 08:24:10

CALGARY, April 11, 2014 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr. Alan Melcher, Professor of Clinical Oncology and Biotherapy at the University of Leeds, presented at the 8(th) Annual International Conference on Oncolytic Virus Therapeutics held in Oxford, UK. Dr. Melcher's presentation, titled "Clinical Virotherapy and Immune Modulation; Bench to Bedside and Back Again," covered early clinical research showing that...

2014-04-04 12:35:32

Using magnetically controlled nanoparticles to force tumor cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden. "The clever thing about the technique is that we can target selected cells without harming surrounding tissue. There are many ways to kill cells, but this method is contained and remote-controlled", said Professor Erik Renström. The point of the new technique is that it is...

2014-04-04 08:25:45

THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Results showed that, while the primary end point of durable response...

2014-03-20 23:02:41

Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. Sacramento, CA (PRWEB) March 20, 2014 Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The...

2014-03-17 12:27:23

Union Creates Global Leader In Targeted Oncolytic Immunotherapy BUSAN, South Korea and SAN FRANCISCO, March 17, 2014 /PRNewswire/ -- SillaJen, Inc., a privately-held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, announced today that it had completed the acquisition of San Francisco-based Jennerex, Inc. Privately-held Jennerex is a clinical-stage, biotherapeutics company recognized as a global leader in the development of...

2014-03-14 16:23:20

Data Showed Tumor Shrinkage in Both Injected and Metastasized Tumors THOUSAND OAKS, Calif., March 14, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts of the body. The analysis recorded tumor-level responses from a pivotal Phase 3 study evaluating...

2014-03-06 13:13:25

Ludwig researchers show that infecting just 1 tumor with a virus could boost the systemic effectiveness of cancer immunotherapy A Ludwig Cancer Research study suggests that the clinical efficacy of checkpoint blockade, a powerful new strategy to harness the immune response to treat cancers, might be dramatically improved if combined with oncolytic virotherapy, an investigational intervention that employs viruses to destroy tumors. Published today in the journal Science Translational...

2014-01-27 14:42:53

Cancer is the leading cause of death in Canada and is responsible for about 30% of all deaths, according to the Canadian Cancer Society. Despite the urgent need for new and effective drugs, it remains extremely difficult to develop anti-cancer therapies in a timely way. Researchers in Ottawa looked at how to leverage current experimental therapies, in different combinations, to speed the fight against cancer. Scientific evidence suggests a specific combination approach is effective, as...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related